New inflammasome inhibitor published in Nature Medicine

Congratulations to Dr Rebecca Coll, for publishing her research, characterising a small-molecule inhibitor of the NLRP3 inflammasome, in the prestigious journal Nature Medicine. Rebecca and her colleagues discovered that a compound called MCC950, specifically inhibits the NLRP3 inflammasome and has anti-inflammatory effects in animal models of inflammatory disease. This discovery highlights the promise of an NLRP3 small molecule inhibitor in the treatment of inflammatory diseases.

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine 21(3):248-55. Pubmed link

Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KHG, Masters SL, Schroder K, Cooper MA, O’Neill LAJ (2015).

Update:
This publications has been the subject of 6 commentaries and 25 international news articles, including those in; The Journal (Ireland), Science Newsline, redOrbit, Today Topics, Medical News Today, The Medical News, Health Medicine Network, Business Standard, Drug Discovery and Development, Tech Times, Health Canal, MedicalXpress, Innovations Report, Science Daily, EurekAlert!, Bioportfolio, Rheumatoid Arthritis News, and more.
Read the full list of news articles at Nature Medicine

Comment in:
Inflammasome inhibition: putting out the fire. Cell Metabolism
Inflammation. Potent small molecule extinguishes the NLRP3 inflammasome. Nature Reviews Rheumatology
The Nlrp3 inflammasome admits defeat. Trends in Immunology
Inflammasome: starving inflammation. Nature Reviews Immunology